Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing

References

• Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G, Schwarz TF, Catteau G, Lal H, Heineman TC. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34(6):863–868. doi:10.1016/j.vaccine.2015.09.073.
   PubMed Web of Science ®Google Scholar
• Watanabe D, Mizukami A, Holl K, Curran D, Van Oorschot D, Varghese L, Shiragami M. The potential public health impact of herpes zoster vaccination of people aged≥ 50 years in Japan: results of a Markov model analysis. Dermatol Ther (Heidelb). 2018;8(2):269–284. doi:10.1007/s13555-018-0236-3.
   PubMed Web of Science ®Google Scholar
• van Oorschot DA, Hunjan M, Bracke B, Lorenc S, Curran D, Starkie-Camejo H. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. BMJ Open. 2019;9(5):e025553. doi:10.1136/bmjopen-2018-025553.
   PubMed Web of Science ®Google Scholar
• Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8(1):1-13. doi:10.1186/1741-7015-8-37.
   Web of Science ®Google Scholar
• Kawai K, Rampakakis E, Tsai T-F, Cheong HJ, Dhitavat J, Covarrubias AO, Yang L, Cashat-Cruz M, Monsanto H, Johnson K, et al. Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia. Int J Infect Dis. 2015;34:126–131. doi:10.1016/j.ijid.2015.03.022.
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpää ML, McKendrick MW, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–S26. doi:10.1086/510206.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Bruxvoort K, Ackerson B, Luo Y, Tanenbaum H, Tian Y, Zheng C, Cheung B, Patterson BJ, Van Oorschot D, et al. The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥50 years old: incidence, complications, hospitalization, mortality, and recurrence. J Infect Dis. 2020;222(5):798–806. doi:10.1093/infdis/jiz652.
   PubMed Web of Science ®Google Scholar
• Yu SY, Fan BF, Yang F, DiBonaventura M, Chen YX, Li RY, King-Concialdi K, Kudel I, Hlavacek P, Hopps M, et al. Patient and economic burdens of postherpetic neuralgia in China. Clinicoecon Outcomes Res. 2019;11:539–550. doi:10.2147/CEOR.S203920.
   PubMed Web of Science ®Google Scholar
• Weinke T, Glogger A, Bertrand I, Lukas K. The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany. Sci World J. 2014;2014:749698. doi:10.1155/2014/749698.
   Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1–30.
   PubMedGoogle Scholar
• Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928–930. doi:10.1212/WNL.0b013e3182a3516e.
   PubMed Web of Science ®Google Scholar
• Yin D, Van Oorschot D, Jiang N, Marijam A, Saha D, Wu Z, Tang H, Diaz-Decaro J, Watson P, Xie X, et al. A systematic literature review to assess the burden of herpes zoster disease in China. Expert Rev Anti Infect Ther. 2021;19(2):165–179. doi:10.1080/14787210.2020.1792290.
   PubMed Web of Science ®Google Scholar
• Lu L, Suo L, Li J, Pang X. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China. Hum Vaccin Immunother. 2018;14(11):2632–2635. doi:10.1080/21645515.2018.1489193.
   PubMed Web of Science ®Google Scholar
• Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866.
   PubMed Web of Science ®Google Scholar
• National Medical Products Administration. China prescribing information for recombinant zoster vaccine (Shingrix). In: Prescribing information for recombinant zoster vaccine (Shingrix). GSK China; 2019.
   Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New Engl J Med. 2015;372(22):2087–2096. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New Engl J Med. 2016;375(11):1019–1032. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Muscatello DJ, Wang Q, Yang P, Wu J, MacIntyre CR. Overview of influenza vaccination policy in Beijing, China: current status and future prospects. J Public Health Policy. 2017;38(3):366–379. doi:10.1057/s41271-017-0079-7.
   PubMed Web of Science ®Google Scholar
• Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213–2221. doi:10.1080/21645515.2017.1345399.
   PubMed Web of Science ®Google Scholar
• Volpi A, Boccalini S, Dari S, Clarke C, Curran D, Loiacono I, Pitrelli A, Puggina A, Tosatto R, Van Oorschot D, et al. The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy. Hum Vaccin Immunother. 2020;16(2):327–334. doi:10.1080/21645515.2019.1657753.
   PubMed Web of Science ®Google Scholar
• McGirr A, Tara B, Wortzman M, Millson B, McNeil S. An early look at the second dose completion of the recombinant zoster vaccine (RZV) in Canadian adults - a retrospective analysis. In Canadian Immunization Conference; 2020 Dec 1-3.
   Google Scholar
• China Statistics Press. Beijing statistical yearbook 2019. 3-1 basic statistics on population census. [accessed 2020 Nov]. http://nj.tjj.beijing.gov.cn/nj/main/2019-tjnj/zk/indexeh.htm.
   Google Scholar
• Global Burden of Disease Study 2017 (GBD 2017) Life Tables 1950-2017 [Internet] Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2018. [accessed 2020 Nov]. http://ghdx.healthdata.org/record/ihme-data/gbd-2017-life-tables-1950-2017.
   Google Scholar
• Jiang W, Li G, Xu Y, Pei S, Yan Y, Tong H, Wang W, Xu C, Liu Y, Yin D. Epidemiological characteristics of herpes zoster in urban areas of Yichang city during 2016-2017 based on the Yichang Big Data Platform for Health Management [Chinese]. Chin J Vacc Immun. 2019;25(4):82–85.
   Google Scholar
• Shiragami M, Mizukami A, Kaise T, Curran D, Van Oorschot D, Bracke B, Watanabe D. Cost-effectiveness of the adjuvant recombinant zoster vaccine in Japanese adults aged 65 years and older. Dermatol Ther (Heidelb). 2019;9(2):281–297. doi:10.1007/s13555-019-0291-4.
   PubMed Web of Science ®Google Scholar
• Suo L, Zhao D, Pan J, Wang Y, Wang Q, Wang H, Peng X, Wang X, Zhu Z, Wang Y, et al. Analysis of herpes zoster incidence and hospitalization in three areas of Beijing in 2015 based on health information system of medical institutions. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]. 2019;53(5):503–507. doi:10.3760/cma.j.issn.0253-9624.2019.05.013.
   PubMedGoogle Scholar
• Herpes Zoster Expert Consensus Working Group of the Dermatologist Branch of the Chinese Medical Doctor Association. Chinese expert consensus on herpes zoster [Chinese]. Chin J Dermatol. 2018;51(6):403–408.
   Google Scholar
• Yawn et al., Mayo Clin Proc. 2007;82(11):1314–1349.
   Google Scholar
• Yawn BP, Wollan PC, Kurland MJ, Sauver JLS, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011;86(2):88–93. doi:10.4065/mcp.2010.0618.
   PubMed Web of Science ®Google Scholar
• Jiang J, Zoster-006 and -022 Study Group. Efficacy and safety of the adjuvanted recombinant zoster vaccine in Asian Adults ≥ 50 years of age: a post-hoc analysis of the phase III zoster-006 and −022 Studies. In 15th Annual Meeting of China Dermatologist Association & National Congress of Cosmetic Dermatology; Xiamen, Fujian, China 2019 Nov 7-10.
   Google Scholar
• Hobbelen PH, Stowe J, Amirthalingam G, Miller L, van Hoek AJ. The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J Infect. 2016;73(3):241–253. doi:10.1016/j.jinf.2016.05.008.
   PubMed Web of Science ®Google Scholar
• Feng Q, Yeung WJJ, Wang Z, Zeng Y. Age of retirement and human capital in an aging China, 2015–2050. Eur J Popul. 2019;35(1):29–62. doi:10.1007/s10680-018-9467-3.
   PubMed Web of Science ®Google Scholar
• McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, Varghese L, Curran D. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17(5):723–732. doi:10.1007/s40258-019-00491-6.
   PubMed Web of Science ®Google Scholar
• China Statistics Press. 2-4 life expectancy at birth. China statistical yearbook 2019. [accessed 2020 Nov]. http://www.stats.gov.cn/tjsj/ndsj/2019/indexeh.htm.
   Google Scholar
• Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. 2019;74(8):1231–1238. doi:10.1093/gerona/gly150.
   PubMed Web of Science ®Google Scholar